Rapid response to selpercatinib in RET fusion positive pancreatic neuroendocrine carcinoma confirmed by smartwatch.

MLA

Deschler-Baier, Barbara, et al. “Rapid Response to Selpercatinib in RET Fusion Positive Pancreatic Neuroendocrine Carcinoma Confirmed by Smartwatch.” NPJ Precision Oncology, vol. 8, no. 1, July 2024, p. 167. EBSCOhost, https://doi.org/10.1038/s41698-024-00659-x.

APA

Deschler-Baier, B., Krebs, M., Kroiss, M., Chatterjee, M., Gundel, D., Kestler, C., Kerscher, A., Kunzmann, V., Appenzeller, S., Maurus, K., Rosenwald, A., Bargou, R., Gerhard-Hartmann, E., & Venkataramani, V. (2024). Rapid response to selpercatinib in RET fusion positive pancreatic neuroendocrine carcinoma confirmed by smartwatch. NPJ Precision Oncology, 8(1), 167. https://doi.org/10.1038/s41698-024-00659-x

Chicago

Deschler-Baier, Barbara, Markus Krebs, Matthias Kroiss, Manik Chatterjee, Daniel Gundel, Christian Kestler, Alexander Kerscher, et al. 2024. “Rapid Response to Selpercatinib in RET Fusion Positive Pancreatic Neuroendocrine Carcinoma Confirmed by Smartwatch.” NPJ Precision Oncology 8 (1): 167. doi:10.1038/s41698-024-00659-x.